Warma Neil K 4

What Happened Neil K. Warma, CEO of ProMIS Neurosciences, acquired 6,183 common shares and Common Share Warrants to purchase 6,183 common shares on February 3, 2026 pursuant to a Securities Purchase Agreement with selected investors. The Form 4 reports the common shares were purchased at $12.13 each (cash reported for the shares: $75,000). The purchase agreement states the Common Share Warrants were also priced at $12.13 each; the warrants are reported separately as a derivative acquisition on the filing.

Key Details

• Transaction date: February 3, 2026; Form 4 filed February 5, 2026 (appears timely).
• Common shares acquired: 6,183 @ $12.13; cash reported for shares = $75,000.
• Derivative acquired: 6,183 Common Share Warrants (reported as N/A value on the Form 4); purchase agreement lists $12.13 per warrant.
• Shares owned after transaction: not specified in the filing.
• Footnotes: F1 confirms the acquisition was under a Securities Purchase Agreement; F2 states the warrants expire the earlier of February 3, 2031 or within 60 days after public announcement or Form 8‑K reporting topline data from cohorts treated with single ascending doses of PMN310.

Context This was a private placement (not an open‑market trade) that increased the CEO’s direct common‑share holdings and also added warrants (a standard derivative giving the right to buy shares later). The warrants’ expiration condition ties to a clinical topline data announcement for PMN310, which is notable for timing of potential exercise but does not by itself indicate intent to exercise. Purchases by executives are often watched by investors as a positive signal, but filings are factual records and do not reveal the insider’s motivations.